Select Advanced Solid Tumors

Oncology

12 drugs in development·4 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
tebentafusp	Immunocore Holdings plc (IMCR)

Phase 2(1)

Drug	Company
Interleukin-2	Filana Therapeutics Inc. (FLNA)

Phase 1(10)

Drug	Company
brenetafusp	Immunocore Holdings plc (IMCR)
Brenetafusp and chemotherapy	Immunocore Holdings plc (IMCR)
Brenetafusp and kinase inhibitors	Immunocore Holdings plc (IMCR)
Brenetafusp and monoclonal antibodies and chemotherapy	Immunocore Holdings plc (IMCR)
Brenetafusp and tebentafusp	Immunocore Holdings plc (IMCR)
Interleukin-2	Merus N.V. (MRUS)
KSQ-001EX	ENANTA PHARMACEUTICALS INC (ENTA)
KSQ-004EX	Merus N.V. (MRUS)
KSQ-004EX	ENANTA PHARMACEUTICALS INC (ENTA)
KSQ-004EX	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 12 drugs in development for Select Advanced Solid Tumors across 4 companies.

There are 2 clinical trials targeting Select Advanced Solid Tumors tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.